All News
Disease-modifying therapies and Coronavirus disease
May 3, 2021Study investigating the severity of Coronavirus disease in People with Multiple Sclerosisread more
International Progressive MS Alliance e-News
April 18, 2021International Progressive MS Alliance e-News - March 2021 In this issue: • Read about the recent call to action to prioritise research on symptoms that matter most to people affected…read more
Mavenclad quickly reduces MRI lesions in early MS
March 22, 2021Mavenclad (cladribine) reduces the number and volume of lesions in patients at risk of multiple sclerosis (MS) after a first clinical demyelinating event, a study based on Phase 3 trial…read more
ACTRIMS 2021 Conference Review
March 16, 2021The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) forum was held virtually in February this year. The Neurology Research Review have selected and reviewed 10 presentations.read more
Neurology Research Review – Issue 71 – MS Special
March 8, 2021Special issue of Neurology Research Review, focusing specifically on MS.read more
Progressive MS breakthrough treatments – Webinar
March 8, 2021Funded by the International Progressive MS Alliance, a first-of-its-kind global research network aims to develop new, effective treatments for progressive MS.read more
Scientists Discover a Subset of Brain Cells That Fight Inflammation with Instructions from Gut Bacteria
February 11, 2021The Alliance Drug Discovery Collaborative Research Network led by Professor Francisco Quintana at Harvard’s Brigham and Women’s Hospital has reported that a subset of brain cells (astrocytes) may be directed…read more
New possibilities for developing ways to repair nerve-insulating myelin in people with Multiple Sclerosis
February 11, 2021Progressive MS Alliance Collaborative Research Network Study Shows that Stem Cells Derived from Skin Cells of People with MS Make Normal Nerve-Insulating Myelin Results Open More Possibilities for Myelin Repairread more
MBIE Science Whitinga Fellowship
February 11, 2021The MBIE Science Whitinga Fellowship is aimed at supporting excellent early career researchers impacted by COVID-19 in the New Zealand research science system. This is a one-off initiative and will…read more
Demystifying diet and nutrition in MS
January 28, 2021MS Research Australia has funded 3 projects in the 2021 grant round looking at the impact of dietary factors in MS. The projects cover a wide range of possible effects…read more
A potential MS vaccine?
January 27, 2021A recent scientific publication has been touted as highlighting a potential vaccine for MS by some media outlets. So, what does this mean? And how does this tie in with…read more
Covid-19 at the forefront of MS research
January 27, 2021The projects cover a wide range of topics and research areas, including research into COVID-19 in people with MS in Australia.read more
Covid-19 in Ocrelizumab-treated people with Multiple Sclerosis
January 25, 2021This article, written by the Journal of Multiple Sclerosis and related disorders, (MSARD) includes data from clinical trials, post marketing safety surveillance and a US electronic medical records database, Optum.read more
Announcement: PHARMAC consultation: proposal to widen access and transition the process for funded access to multiple sclerosis treatments
November 27, 2020Pharmac have released public consultation on a proposal to widen access to funded multiple sclerosis treatments and transition access from the Multiple Sclerosis Treatment Assessment Committee (MSTAC) Panel to a…read more
2020 Webinar Series – Recordings now available
November 18, 2020These webinars cover the latest in MS research. Highlights include Dr Wallace Brownlee, who dialled in from London to update us on HSCT treatments for MS, and Justin O’Sullivan speaking…read more
New Data: Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis
November 3, 2020New data on the long term benefits of Ocrelizumab for PPMS has recently been published 29 October 2020 on the Lancet Ocrelizumab is currently funded for RRMS in New Zealand…read more
Biotin (MD1003) Fails to Prevent Disability Progression in Progressive MS Patients, Trial Shows
November 3, 2020Note: This article was originally published on www.multiplesclerosisnewstoday.com, written by Marta Figueiredo and fact checked by Patrícia Silva, PHD. MD1003, MedDay Pharmaceuticals’ high-dose biotin therapy, failed to significantly improve functional…read more